

---

# **Update of the Global Plan to Stop TB 2006- 2015**

***Why, when, how?***


Hanoi, Viet Nam  
18<sup>th</sup> CB Meeting, 4th April 2010

Christian Lienhardt



# The Global Plan 2006-15 proposed achievements

---



1. **MDGs for TB and the Partnership's 2015 targets to halve prevalence and death rates globally**
2. **Treatment of 50 million people with TB, 3 million TB/HIV co-infected patients on ARV, and 1.6 million with MDR**
3. **Saving of 14 million lives from 2006-2015**
4. **The first new TB drug introduced by 2010**
5. **The "point of care" diagnostics introduced by 2010**
6. **Develop a new vaccine by 2015**

# TB Control Global Targets

---



## 2015: Goal 6: Combat HIV/AIDS, malaria and other diseases

Target 8: to have halted by 2015 and begun to reverse the incidence...

Indicator 23: incidence, prevalence and deaths associated with TB

Indicator 24: proportion of TB cases detected and cured under DOTS





**2015:** 50% reduction in TB prevalence and deaths relative to 1990 levels

**2050:** elimination (<1 case per million population)



# TB prevalence & mortality



**On track for both indicators in AMR, EMR and SEAR**

**On track for prevalence in WPR**


**Will not be reached in AFR and EUR**

# Global Plan targets – *Research and Development*

	By 2006	By 2010	By 2015
Vaccines	3 vaccines in phase I trials	9 candidates in phase II trials; at least 2 vaccines in "proof of concept" trials; beginning phase III trials	4 phase III trials carried out; one safe, effective vaccine available
Drugs	27 new compounds in the pipeline	1-2 new drugs registered; treatment shortened to 3-4 months	7 new drugs; treatment shortened to 1-2 months
Diagnostics	rapid culture for case detection and DST in demonstration phase	point of care, rapid culture, improved microscopy, phage detection, simplified NAAT	predictive test for LTBI

# Total needs by WG, 2006-2015

GP2: total needs by WG area of responsibility, 2006-2015



# Why do we need to update the Global Plan?

---

1. Regular updates requested by CB (Cairo, 2008)
2. 2010 marks the mid-point of the original plan and is an appropriate time for an update
3. Structural changes – ACSM removed, GLI added
4. Need for a comprehensive up-to-date source of
  - what needs to be done in TB control up to 2015
  - what funding is required for advocacy and to guide country-level planning

➤ *Currently multiple versions/sources of targets and estimates of funding needs are confusing*

# Update of the Global Plan - *Implementation*

---

1. Epidemiological projections far too optimistic, esp. after 2010
2. Better information/methods with which to define burden, trends, targets, costs
3. Covers DOTS, MDR-TB, TB/HIV activities, Technical Assistance + Laboratory strengthening
4. MDR-TB: need for full update to cover all countries
5. TB/HIV: assumption that 50% HIV+ TB patients eligible for ART no longer applicable – should be 100% according to policy
6. GLI/Lab: needs full review and revision by WG, taking into consideration MDR and progress in diagnostics



# Update of the Global Plan - *R&D* (1)

---

- Many R&D targets not on schedule
- Critical review of initial objectives of the Plan and revision to ensure feasibility and achievement
- Following this, definition of activities to reach these objectives
- Set measurable targets and appropriate indicators to evaluate progress
- Define costs according to identified units ensuring comparability between tools and over time.


## Update of the Global Plan - *R&D* (2)

---

- R&D component of the GP was solely relying on activities to be carried out for **New Diagnostics, New Drugs, New Vaccines**
- The update takes into account specific aspects of research to be carried out for MDR-TB, TB/HIV and childhood TB
- Includes basic research (upstream) and operation research (downstream) to cover the full spectrum of TB research
- Establish *on-going evaluation* of progress and funding available through regular comparison with the TAG/STP Survey of Global R&D Funding Investment


# Initial and revised cost estimates for new drugs, diagnosis and vaccines

## 5-year Total R&D Needs, 2011-2015



\*excludes implementation of BCG vaccine

# Timelines and deadlines



## ***Expectations***

---

- A revised GP that:
  - strongly signals the need for an upsurge in activities to reach MDGs and STP targets
  - is an advocacy document and a roadmap for countries and STP partners for the next 5 years
  - includes all progress made in the last 5 years
  - strengthens collaborations between disciplines and constituencies
  - has ambitious but realistic goals